Method for forestalling the hook effect in a multi-ligand immunoassay system

• US 4,743,542 A
• Filed: 04/11/1985
• Issued: 05/10/1988
• Est. Priority Date: 04/11/1985
• Status: Expired due to Term

• Current Assignee: Ortho Diagnostic Systems, Inc. (The Carlyle Group LP (Corporate Private Equity))
• Original Assignee: Ortho Diagnostic
• Inventors: Lisi, Peter, Graham, Henry A. Jr.
• Primary Examiner(s): Marantz, Sidney
• Application Number:
  US06/722,566
• Time in Patent Office: 1,125 Days
• Field of Search: 435/4, 435/7, 436/518, 436/528, 436/531, 436/534, 436/817, 436/501, 436/533, 436/548, 436/818
• US Class Current: 435/7.94
• CPC Class Codes: G01N 33/54393 Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
• CPC Class Codes: Y10S 435/962 Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
• CPC Class Codes: Y10S 435/968 High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
• CPC Class Codes: Y10S 436/818 Human chorionic gonadotropin

Abstract

A method is provided for substantially increasing the dynamic range of an immunoassay and forestalling the hook effect observed with very large ligand concentrations in aqueous samples. The method comprises the addition of ligand binding partners which do not have labels associated therewith to compete with labeled ligand binding partners thereby effectively eliminating the presence of the excess ligand in the sample solution. The conversant method for ligand binding partner immunoassays is also provided.

Claims

1. In an immunoassay for the detection of a ligand wherein a first ligand binding partner specific for the ligand to be detected is immobilized by attachment to an insoluble surface and is reacted with a second ligand binding partner specific for the ligand to be detected, said second ligand binding partner having a detectable label and forming a sandwich complex with said first binding partner in accordance with the presence or absence of the ligand to be detected, the improvement comprising:

(a) providing a haptenated first ligand binding partner and an insoluble isotactic surface means capable of reacting with and immobilizing said haptenated first binding partner; and

(b) adding to said reactants either additional non-haptenated first ligand binding partner or non-labeled second ligand binding partner or a combination thereof, so as to bind excess ligand to be detected and permit formation of an increased number of sandwich complexes thereby increasing the dynamic range of detection sensitivity to said immunoassay.

2. The immunoassay of claim 1, wherein the first ligand binding partner is haptenated with a fluorescent molecule.

3. The immunoassay of claim 1, wherein the isotactic surface means is a latex bead coated with anti-hapten monoclonal antibody.

5. The immunoassay of claim 1 or claim 4, wherein the ligand is an antigen.

6. The immunoassay of claim 1 or claim 4, wherein the first ligand binding partner is a monoclonal antibody.

7. The immunoassay of claim 1 or claim 4, wherein the second ligand binding partner is a monoclonal antibody.

8. The immunoassay of claim 1 or claim 4, wherein the detectable label is a fluorescent or enzyme label.

9. The immunoassay of claim 1 or claim 4, wherein the dynamic range of detection sensitivity is increased by a factor of about 2.5.

4. In an immunoassay for the detection of a ligand wherein a first ligand binding partner associated with an insoluble surface and specific for the ligand to be detected is reacted with a second ligand binding partner specific for the ligand to be detected, said second ligand binding partner having a detectable label and forming a sandwich complex with said first binding partner in accordance with the presence or absence of the ligand to be detected, the improvement comprising:

adding to said reactants either additional first ligand binding partner not associated with said insoluble surface or non-labeled second ligand binding partner or a combination thereof, so as to bind excess ligand to be detected and permit formation of an increased number of sandwich complexes thereby increasing the dynamic range of detection sensitivity of said immunoassay.